<DOC>
	<DOCNO>NCT00194064</DOCNO>
	<brief_summary>Inpatient Study Evaluating Safety Efficacy Open-Label Olanzapine Monotherapy Treatment Refractory Bipolar Mania : This study recruit adult subject diagnose Bipolar I Disorder presently experience episode mania . Patients must willing spend initial 7 day hospital observe response medication . Patients must refractory ( intolerant non-responsive ) treatment lithium valproate carbamazepine . Patients receive study-related care cost . This study sponsor Eli Lilly Company .</brief_summary>
	<brief_title>Pilot Study Evaluating Safety Efficacy Open-Label Olanzapine</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>The subject satisfy Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criteria primary diagnosis Bipolar Disorder , recently manic The patient willing hospitalized inpatient psychiatric unit minimum seven ( 7 ) day . Subject treat lithium past . Subject treat divalproex carbamazepine past . Subject treat Haldol haloperidol past . Subjects lacks capacity provide inform consent Subject serious suicide risk medically unstable condition judge investigator Subject dependent drug ( nicotine caffeine ) last three ( 3 ) month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>